Skip to main content
. Author manuscript; available in PMC: 2023 Apr 26.
Published in final edited form as: Cancer Cell. 2019 Apr 8;35(4):573–587.e6. doi: 10.1016/j.ccell.2019.03.002

Figure 8. Pharmacologic inhibition of EGFR in combination with c-RAF knockdown inhibits proliferation of PDAC cells derived from PDX tumor models.

Figure 8.

Cell proliferation of the indicated PDX-derived cells infected with scramble shRNA (black), infected with shRNA R1 against c-RAF (red), infected with shRNA R1 against c-RAF and exposed to Gefitinib (IC50) (green), infected with shRNA R1 against c-RAF and exposed to Erlotinib (IC50) (blue) (left) and Western blot analysis of c-RAF expression in whole cell extracts obtained from the indicated PDX-derived cells using either a scramble shRNA (−) or a shRNAs against c-RAF (R1) (right). Proliferation was determined by CellTiter-Glo and expressed as fold increase in the number of cells determined at each of the indicated days. Error bars indicate mean ± SD. GAPDH served as loading control in Western blot.

See also Table S4.